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Trials of anemia correction in chronic kidney disease have
found either no benefit or detrimental outcomes of higher
targets. We did a secondary analysis of patients with chronic
kidney disease enrolled in the Correction of Hemoglobin in
the Outcomes in Renal Insufficiency trial to measure the
potential for competing benefit and harm from achieved
hemoglobin and epoetin dose trials. In the 4 month analysis,
significantly more patients in the high-hemoglobin
compared to the low-hemoglobin arm were unable to
achieve target hemoglobin and required high-dose
epoetin-a. In unadjusted analyses, the inability to achieve
a target hemoglobin and high-dose epoetin-a were each
significantly associated with increased risk of a primary
endpoint (death, myocardial infarction, congestive heart
failure or stroke). In adjusted models, high-dose epoetin-a
was associated with a significant increased hazard of a
primary endpoint but the risk associated with randomization
to the high hemoglobin arm did not suggest a possible
mediating effect of higher target via dose. Similar results
were seen in the 9 month analysis. Our study demonstrates
that patients achieving their target had better outcomes than
those who did not; and among subjects who achieved their
randomized target, no increased risk associated with the
higher hemoglobin goal was detected. Prospective studies
are needed to confirm this relationship and determine safe
dosing algorithms for patients unable to achieve target
hemoglobin.
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Recombinant erythropoietin revolutionized the care of
patients with chronic kidney disease (CKD) and end-stage
renal disease (ESRD)1,2 reducing blood transfusions and
complications like iron overload. Although initial therapy
was aimed at partial anemia correction, observational studies
suggested that treatment with erythropoietin-stimulating
agents (ESA) to higher targets was associated with improved
survival.3,4 Three randomized trials of anemia correction in
CKD and ESRD patients, however, failed to demonstrate a
benefit of higher hemoglobin targets.5–8 In fact, the final
analyses of one trial unexpectedly demonstrated harm among
subjects randomized to higher targets.5
Two factors that may contribute to worse outcomes with
higher targets include failure to attain target and higher doses
of ESAs. Higher doses of ESAs are required with higher
hemoglobin targets,5,7 and the failure to achieve a hemoglo-
bin target leads to further increases in ESA dose. In an
observational study among patients with ESRD, a lesser
response to therapy as well as higher doses of ESA were
associated with increased mortality.9
This secondary analysis of subjects with CKD enrolled in
the Correction of Hemoglobin and Outcomes in Renal
Insufficiency (CHOIR) trial was undertaken to examine
the potential for competing benefit and harm from achieved
dose of hemoglobin and epoetin. Specifically, this analysis
examines the associations between ESA dose, inability to
achieve hemoglobin target, and clinical outcomes.
RESULTS
Four-month landmark analysis
Baseline characteristics including markers of inflammation,
such as albumin and ferritin, were similar between groups
analyzed in the 4-month landmark analysis (Table 1,
n¼ 1290). Hemoglobin at baseline and at 3 weeks (before
which subjects all received the same ESA dose) were similar
between groups. Subjects randomized to the high-hemoglo-
bin arm had a higher prevalence of self-reported hyperten-
sion and coronary artery bypass graft (both P¼ 0.03).
In both treatment groups, subjects not achieving their
target hemoglobin within 4 months experienced events at a
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higher rate (Table 2). During this first 4 months, a greater
proportion of subjects in the high-hemoglobin as compared
with the low-hemoglobin group were unable to achieve their
target (37.5 vs 4.7%, Po0.001).
Within each arm, subjects receiving high-dose epoetin-a
experienced events at a higher rate (18.2 vs 12.8% in the
high-hemoglobin and 16.4 vs 10.0% in the low-hemoglobin
groups). A larger proportion of subjects in the high-
hemoglobin as compared with the low-hemoglobin group
required high-dose epoetin-a (35.1 vs 9.6%, Po0.001).
Among subjects not achieving their target, 64.2% received
high-dose epoetin-a as compared with 11.2% among subjects
achieving their target (Po0.001).
The high-hemoglobin as compared with low-hemoglobin
group in the 4-month landmark analysis had an increased
hazard of the primary end point (1.44, CI 1.05–1.97,
Table 1 | Baseline characteristics of subjectsa
Four-month landmark analysis population Nine-month landmark analysis population
High-hemoglobin
group (N=627)
Low-hemoglobin
group (N=633) P-value
High-hemoglobin
group (N=519)
Low-hemoglobin
group (N=538) P-value
Age, year 65.9 (14.2) 66.6 (13.2) 0.37 65.7 (14.3) 66.4 (13.2) 0.41
Female sex (%) 56.5% 54.0% 0.39 57.4% 54.1% 0.28
Race (%) 0.74 0.53
White 62.7% 61.6% 63.5% 60.8%
Black 28.0% 29.5% 28.6% 30.5%
American-Indian or Alaskan Native 0.2% 0.5% 0.2% 0.6%
Asian or Pacific Islander 3.7% 2.8% 3.1% 2.2%
Other 5.4% 5.5% 4.6% 5.9%
Hispanic ethnic background (%) 12.3% 13.1% 0.67 12.6% 13.4% 0.69
History of smoking tobacco (%) 46.6% 43.8% 0.31 45.1% 43.3% 0.57
Cause of CKD (%) 0.50 0.66
Diabetes mellitus 46.4% 49.7% 45.8% 48.6%
Hypertension 30.2% 28.3% 30.9% 29.1%
Other 23.4% 22.1% 23.3% 22.3%
Cardiovascular history (%)
Hypertension 95.8% 92.9% 0.03 95.2% 92.4% 0.07
Myocardial infarction 14.8% 14.6% 0.92 14.6% 13.6% 0.66
CABG 17.9% 13.2% 0.03 16.7% 12.5% 0.05
PCI 9.4% 10.8% 0.43 9.6% 10.9% 0.50
Congestive heart failure 22.0% 20.7% 0.58 21.0% 18.9% 0.41
Atrial fibrillation 8.1% 8.8% 0.66 8.2% 7.8% 0.81
Stroke 9.5% 9.0% 0.74 9.8% 9.2% 0.75
Lower-extremity amputation 3.2% 2.8% 0.71 3.2% 2.5% 0.53
MI, CABG, or PCI 26.3% 25.0% 0.59 26.1% 23.7% 0.37
Body Mass Index (kg/m2) 30.5 (7.8) 30.4 (7.5) 0.85 30.5 (7.6) 30.7 (7.7) 0.69
GFR (ml/min/m2) 27.1 (8.7) 27.6 (9.1) 0.30 27.5 (8.7) 28.3 (9.1) 0.14
Baseline hemoglobin (g/100 ml) 10.1 (0.86) 10.1 (0.85) 0.78 10.1 (0.85) 10.1 (0.84) 0.28
Week 3 hemoglobin (g/100 ml) 10.7 (0.94) 10.6 (0.94) 0.10 10.7 (0.95) 10.6 (0.94) 0.50
Baseline albumin (g/10 ml) 3.8 (0.51) 3.8 (0.46) 0.35 3.8 (0.47) 3.8 (0.45) 0.94
Baseline phosphorus (mg/100 ml) 4.1 (0.73) 4.1 (0.74) 0.36 4.1 (0.73) 4.0 (0.73) 0.12
Baseline cholesterol (mg/100 ml) 184.6 (50.2) 183.5 (47.9) 0.70 184.5 (48.9) 183.9 (47.7) 0.83
Ratio of total protein/creatinine in urine 1.5 (2.10) 1.4 (2.10) 0.36 1.3 (1.84) 1.2 (1.84) 0.38
Ferritin (ng/ml) 167.8 (157.2) 178.5 (173.1) 0.25 165.9 (158.1) 172.5 (157.0) 0.50
Transferrin saturation (%) 25.3 (11.7) 24.6 (10.1) 0.29 25.2 (11.8) 24.7 (10.2) 0.43
Transferrin saturation o20% (%) 36.1% 33.9% 0.40 36.1% 33.9% 0.44
Medications (%)
ACE inhibitor or ARB 75.8% 75.3% 0.84 77.5% 76.8% 0.80
Beta blocker 45.0% 47.9% 0.30 44.9% 47.7% 0.36
HMG CoA reductase inhibitor 52.3% 53.0% 0.79 54.4% 55.0% 0.85
Iron
Intravenous 2.9% 1.8% 0.18 3.1% 2.1% 0.28
Oral 27.1% 25.8% 0.60 26.8% 24.1% 0.32
Not specified 3.4% 1.6% 0.04 3.3% 2.4% 0.06
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; CKD, chronic kidney disease; GFR, glomerular filtration rate;
HMG CoA, 3-hydroxy-3-methyl-glutaryl coenzyme A; PCI, percutaneous coronary intervention; MI, myocardial infarction.
aContinuous variables reported as means (s.d.) unless noted otherwise.
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P¼ 0.02) (Table 3, Figure 1). When inability to achieve target
hemoglobin and use of high-dose epoetin-a were added to
the model with treatment arm separately, treatment arm was
not significant, and inability to achieve target or use of high-
dose epoetin-a were significant predictors (P¼ 0.05 and
0.003). When dose, target, and inability to achieve target were
entered, only high-dose epoetin-a remained significant
(HR¼ 1.60, CI 1.08–2.38, P¼ 0.02). In the adjusted model,
high-dose epoetin-a was associated with a 57% increased
hazard of the primary composite end point (HR 1.57, CI
1.04–2.36, P¼ 0.03) (Table 3, Figure 1). As treatment
assignment to higher target is significantly associated with
inability to achieve target and use high-dose epoetin-a by the
landmark time point, this suggests that detrimental outcome
of higher target in CHOIR trial may be mediated through the
use of high dose. No significant interactions were present
between achieved hemoglobin, high-dose ESA, or treatment
arm (all P40.10).
A restricted cubic spline Cox regression model was fitted
to examine the relationship of average dose before the 4-
month landmark time point with outcome. In the low-
hemoglobin group (median average epoetin dose 5623,
25–75% IQR 3959–8376 U), the relationship between dose
and log hazard surrounding the majority of observations
appear to be J-shaped (Figure 2a), although the confidence
interval widens at higher dosing levels. In the high-
hemoglobin group (median epoetin dose 10,786, IQR
7803–14,114 U), the relationship between dose and log hazard
surrounding the majority of observations appears to be
linear (Figure 2b).
Nine-month landmark analysis
Findings of the 9-month landmark analysis were similar to
those of the 4-month analysis. Among subjects included in
the 9-month landmark analysis (n¼ 1057), factors reflecting
inflammation were similar between treatment arms (Table 1).
Subjects not achieving their target hemoglobin within the
first 9 months of the trial experienced events at a higher rate
(Table 2). During these first 9 months, a greater proportion
of subjects in the high-hemoglobin, as compared with the
low-hemoglobin group, were unable to achieve their target
hemoglobin (14.8 vs 0.7%, Po0.001).
Within the high-hemoglobin group, subjects receiving
high-dose epoetin-a experienced events at a higher rate (13.8
vs 9.5%). Event rates for high- vs low-dose epoetin-a were
similar in the low-hemoglobin group (7.2 vs 7.7%). A larger
proportion of subjects in the high-hemoglobin as compared
with the low-hemoglobin group required high-dose epoetin-
a (57.2 vs 15.4%, Po0.001). Among subjects not achieving
their target, 86.4% required high-dose epoetin-a as com-
pared with 31.8% among subjects achieving their target
(Po0.001).
Randomization to the high-hemoglobin as compared with
the low-hemoglobin group was associated with an increased
hazard of primary end point (1.62, CI 1.09–2.40, P¼ 0.02)
(Table 3, Figure 1). When added to models containing
treatment arm, inability to achieve target and high-dose
epoetin-a separately were predictors of worse outcomes
(P¼ 0.02 and 0.05). When dose, target, and inability to
achieve target were entered, inability to achieve target
trended toward a significant association with outcomes
Table 2 | Description of achieved hemoglobin, epoetin-a dose, and outcomes in 4- and 9-month landmark analysis
Four-month landmark analysis population Nine-month landmark analysis population
High-hemoglobin (n=627) Low-hemoglobin (n=633) High-hemoglobin (n=519) Low-hemoglobin (n=538)
Achieved hgbo11.1, N (%) 36 (5.7%) 30 (4.7%) 4 (0.8%) 4 (0.7%)
Max hgb g/100 ml, mean (s.d.) 10.2 (0.80) 10.3 (0.68) 10.9 (0.10) 10.9 (0.19)
Composite events (%) 9 (25.0%) 3 (10.0%) 2 (50.0%) 0
High-dose ESA (%) 30 (83.3%) 19 (63.3%) 4 (100.0%) 3 (75.0%)
Achieved hgb 11.1–13.1, N (%) 199 (31.7%) 443 (70.0%) 73 (14.1%) 351 (65.2%)
Max hgb g/100 ml, mean (s.d.) 12.2 (0.57) 12.3 (0.47) 12.3 (0.46) 12.5 (0.38)
Composite events (%) 34 (17.1%) 49 (11.1%) 13 (17.8%) 32 (9.1%)
High-dose ESA (%) 121 (60.8%) 35 (7.9%) 63 (86.3%) 57 (16.2%)
Achieved hgbX13.1 392 (62.5%) 160 (25.3%) 442 (85.2%) 183 (24.0%)
Max hgb g/100 ml, mean (s.d.) 14.2 (0.70) 13.6 (0.58) 14.6 (0.69) 13.6 (0.59)
Composite events (%) 49 (12.5%) 15 (9.4%) 47 (10.6%) 9 (4.9%)
High-dose ESA (%) 69 (17.6%) 7 (4.4%) 230 (52.0%) 23 (12.6%)
High-dose ESA, N (%) 220 (35.1%) 61 (9.6%) 297 (57.2%) 83 (15.4%)
Max dose ESA, mean (s.d.) 20,123 (769.5) 20,033 (256.1) 20,088 (766.1) 20,024 (219.5)
Composite events (%) 40 (18.2%) 10 (16.4%) 41 (13.8%) 6 (7.2%)
Max hgb g/100 ml 12.4 (1.39) 11.5 (1.26) 14.0 (1.16) 12.7 (0.89)
Low-dose ESA (%) 407 (64.9%) 572 (90.4%) 222 (42.8%) 455 (84.6%)
Max dose ESA, mean (s.d.) 13,162 (2988.2) 11,533 (2577.8) 14,185 (2917.4) 11,933 (2615.7)
Composite events (%) 52 (12.8%) 57 (10.0%) 21 (9.5%) 35 (7.7%)
Max hgb g/100 ml, mean (s.d.) 13.9 (1.08) 12.6 (0.79) 14.6 (0.76) 12.9 (0.69)
hgb, hemoglobin.
Bold-faced numbers represent the patients who did not achieve their hgb target within their randomized group.
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(HR¼ 1.76, CI 0.97–3.20, P¼ 0.06), and high-dose epoetin-a
therapy held a similar point estimate as was seen in the
4-month landmark, however, no longer reaching statistical
significance (HR¼ 1.40, CI 0.90–2.19, P¼ 0.13). In the
adjusted model, relationships were similar (Table 3, Figure 1).
Again, the restricted cubic spline Cox regression model
shows that in the low-hemoglobin group (median epoetin
dose 4513, IQR 2949–7026 U), the relationship between dose
and log hazard surrounding the majority of observations may
be J-shaped (Figure 2c), although the confidence interval
widens at higher dosing levels. In the high-hemoglobin group
(median epoetin dose 10,692, IQR 7821–14,410 U), the
relationship between dose and log hazard surrounding the
majority of observations was linear (Figure 2d).
DISCUSSION
Although complete correction of anemia of kidney disease
with epoetin-a has been associated with increased mortality
compared with partial correction,5,8 the underlying mechan-
isms are not clear. This post hoc analysis of CHOIR generates
the hypothesis that toxicities related to high-dose epoetin-a
may contribute to worse outcomes among subjects with
Table 3 | Cox proportional hazards models for the primary composite endpoint of death, coronary heart failure hospitalization,
stroke, or MI
Four-month landmark analysis N=1260 Nine-month landmark analysis N=1057
Variable HR, 95% CI P-value HR, 95% CI P-value
Model 1
Target arm (high vs low) 1.44, 1.05–1.97 0.02 1.62, 1.09–2.40 0.02
Model 2
Target arm (high vs low) 1.26, 0.89–1.78 0.20 1.44, 0.95–2.18 0.09
Not achieving hemoglobin target 1.46, 1.00–2.13 0.05 1.99, 1.12–3.55 0.02
Model 3
Target arm (high vs low) 1.26, 0.90–1.75 0.18 1.37, 0.89–2.11 0.15
High-dose ESA 1.71, 1.20–2.43 0.003 1.54, 1.00–2.35 0.05
Model 4
Target arm (high vs low) 1.21, 0.85–1.71 0.29 1.28, 0.82–2.00 0.27
Not achieving hemoglobin target 1.17, 0.76–1.79 0.47 1.76, 0.97–3.20 0.06
High-dose ESA 1.60, 1.08–2.38 0.02 1.40, 0.90–2.19 0.13
Model 5 N=1192 N=1016
Target arm (high vs low) 1.17, 0.81–1.68 0.41 1.25, 0.80–1.97 0.33
Not achieving hemoglobin target 1.21, 0.78–1.89 0.39 1.80, 0.97–3.34 0.06
High-dose ESA 1.57, 1.04–2.36 0.03 1.48, 0.94–2.32 0.09
Self-reported hypertension 0.94, 0.48–1.85 0.86 0.66, 0.32–1.37 0.27
Previous CABG 2.44, 1.70–3.49 o0.01 1.75, 1.08–2.86 0.02
Use of IV iron 0.47, 0.12, 1.90 0.29 0.36, 0.05, 2.63 0.32
CABG, coronary artery bypass graft; ESA, erythropoietin-stimulating agent.
Model 1:
Model 2:
Model 3:
Model 4:
Model 5:
Target arm (high vs low)
Target arm (high vs low)
Target arm (high vs low)
Target arm (high vs low)
Target arm (high vs low)
Not Achieving Hgb target
Not achieved Hgb target
Not achieving Hgb target
High-dose ESA
High-dose ESA
High-dose ESA
0 0.5 1 1.5 2 2.5 3 3.5 4 0 0.5 1 1.5 2 2.5 3 3.5 4
Favors Favors
higher lower
Favors Favors
higher lower
4-month landmark analysis 9-month landmark analysis
Figure 1 | Cox proportional hazards models for the primary composite end point of death, coronary heart failure hospitalization,
stroke, or MI.
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higher targets particularly among those who do not achieve
their targeted hemoglobin. Further, this analysis demon-
strates that subjects achieving their target had better
outcomes than those who did not, and among subjects
who achieved their randomized target, no increased risk
associated with the higher hemoglobin goal was detected.
Similar to CHOIR, the Normal Hematocrit study
demonstrated a relative risk of 1.28, 95% CI 0.92, 1.78,
favoring the low-hematocrit group.8 Subjects achieving the
higher target had a lower mortality rate than subjects in the
lower-hematocrit group.7 Higher hemoglobin values alone in
both the Normal Hematocrit study and CHOIR were not
associated with worse outcomes. Rather, lower achieved
values appeared to be associated with higher mortality.
Additionally, in the Normal Hematocrit study, following
cessation of the target intervention, subjects randomized to
the higher arm had ‘near-identical’ rates of mortality as those
randomized to the lower target.8 Thus, although being
randomized to the higher hemoglobin treatment arm in each
study that resulted in higher rates of adverse outcomes
overall, achieving the higher hemoglobin target was asso-
ciated with lower mortality. And following discontinuation of
the intervention to achieve the higher target, differences
in outcomes are lost. This implies that another factor must
be responsible for these outcomes differences. The analysis
presented here suggests that factor may be high-doses of
epoetin-a.
Epoetin-a requirements are variable among anemic
patients.1,7,9,10 This variability has been attributed to multiple
etiologies, including iron deficiency, infection, and inflam-
mation.9–11 Hyporesponsiveness to epoetin requires higher
doses.12 Among those in the higher target hemoglobin group,
the high doses of epoetin were associated with poorer
outcomes, and when higher epoetin doses were considered in
multivariate analyses, treatment to the higher hemoglobin
target was no longer associated with increased risk, suggest-
ing possible mediating effect of higher target via dose.
Higher doses of epoetin have been demonstrated to be an
independent predictor of mortality in United States Renal
Data Service data of hemodialysis patients.9 Across all
hematocrit categories, significant direct relationships between
dose and mortality were observed. The steepest increases in
risk were found above the 72.5th dose percentile, corre-
sponding to 18,800–29,300 U, similar to the analyses
presented here. However, because of the observational nature
of the United States Renal Data Service data set, the
possibility that relationship between dose and outcome
may reflect confounding due by comorbidity and inflamma-
tion cannot be excluded.
Defining a relationship between dose and outcomes must
attempt to separate the potential contribution of increased
dose requirement as a marker of comorbidity. Two observa-
tional studies have demonstrated relationships between
epoetin dose requirements and clinical factors such as age,
diabetes mellitus, and serum ferritin.12,13 This potential for
confounding limits the ability of a data set with a single
hemoglobin target or dosing strategy to discern whether the
risk detected is associated with dose or with clinical factors
necessitating the dose. However, a trial randomizing to two
targets can take advantage of the benefits of randomization.
If randomization is successful in equally distributing factors
between treatment arms, by definition, factors that are
reflective of inflammation and epoetin-a responsiveness will
also be equally distributed at the baseline. Supporting the
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Figure 2 | Association between epoetin-a dose and primary end point. (a) Among subjects randomized to the low-hemoglobin
group in 4-month landmark analysis. (b) Among subjects randomized to the high-hemoglobin group in the 4-month landmark analysis.
(c) Among subjects randomized to the low-hemoglobin group in 9-month landmark analysis. (d) Among subjects randomized to
the high-hemoglobin group in the 9-month landmark analysis. (The line indicates the log hazard. The bar graph indicates the percent
of treatment arm that fell within each dosing interval.)
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assertion that such factors may be still equally distributed
between arms in CHOIR at the landmark time, key
parameters between treatment groups were similar. To the
extent that albumin and ferritin reflect inflammation, no
difference between treatment groups was detected. Addition-
ally, as a more functional marker, hemoglobin at baseline and
at 3 weeks (before which both treatment groups received the
same dose of epoetin-a) were also similar between groups.
Together, this supports the assertion that there was a
relatively equal distribution of factors reflecting epoetin-a
resistance between arms. In this setting, rates of adverse
events were higher among those treated to the higher
hemoglobin target. Subjects in the high-hemoglobin group
required the use of higher doses of epoetin, which may have
predisposed these patients to a greater dose effect.
The specific mechanisms by which high-doses of epoetin-
a may be associated with a greater risk of adverse outcomes
remain unclear. Erythropoietin receptors have been demon-
strated on human endothelial cells and multiple other
sites.14,15 Additionally, receptors have been found on tumor
cells, suggesting potential roles of erythropoietin as angio-
genic.16–18 Therapy with large episodic doses of erythropoie-
tin do not reflect normal erythropoietin biology and have
unknown effects on erythropoietin receptors.19 Finally, the
nature of the relationship as suggested by these data may not
be linear as seen in previous studies11,20,21 Greater epoetin
resistance or requirements in the ESRD population may alter
key thresholds in this relationship and deserves additional
scrutiny. However, future translational research to investigate
this should allow for the potential that smaller doses may
provoke differential responses or that the beneficial associa-
tion with higher hemoglobin may mask the relationship with
dose within certain ranges.
The Normal Hematocrit trial and other observational
studies have raised concern in the renal community over
potential risks associated with the use of intravenous
iron.7,22–24 Although contradictory studies exist that argue
the presence of this risk,25 it is noteworthy that in the Normal
Hematocrit study more subjects in the higher hemoglobin
arm received intravenous iron and those who received
intravenous iron had a greater odds of mortality compared
with those who did not receive intravenous iron. Although
990 of the 1233 subjects reported in the primary publication
of the Normal Hematocrit study received intravenous iron,
its use was reported in far fewer subjects in CHOIR (n¼ 29).
To fully explore the potential confounding that may exist
between intravenous iron and the relationship presented
here, the use of intravenous iron was included in a
multivariable model revealing stability of all point estimates.
Although this study suggests a relationship between dose
and outcomes, it has limitations. It is a secondary analysis of
a trial designed to test the effect of target but not dose on
outcomes. The ability to generalize dose thresholds to other
populations should be carefully considered given the
volunteerism in trial enrollment. Landmark analyses mini-
mize biases created by differential dropout of subjects and
intervening events between the time of randomization and
the inception time for the outcome measurement. However,
the impact of later hemoglobin levels and doses received after
the landmark time cannot be examined using this methodo-
logy. Hemoglobin target, actual hemoglobin, and dose are
closely related in CHOIR due to the design. Dose is a
consequence of failure to respond. Associations between
outcomes and hemoglobin, dose, or both may be confounded
by factors not available in the CHOIR database. Their
interplay on outcome cannot be definitely isolated without
future, properly designed confirmation study. The conclu-
sions of this analysis should therefore be considered
hypothesis generating. And although hyporesponsiveness
and high-dose requirements for epoetin significantly attenu-
ated the increased risk associated with a higher hemoglobin
target in CHOIR, these factors do not fully explain the
increase in risk. Finally, while increased parathyroid hormone
levels have been associated with an increased mortality risk as
well as an increased risk of ESA resistance among patients
with CKD,26,27 PTH measurements were not performed as a
part of the CHOIR trial and will need to be the subject of
further investigation.
This secondary analysis of the CHOIR trial demonstrates a
relationship between epoetin-a dose and poorer outcomes
beyond the relationship previously appreciated between dose
as a marker of resistance conferred by comorbidity. Current
Food and Drug Administration guidance provides a goal
for epoetin-a therapy focused on a target hemoglobin.
Considerable discussion has recently focused on the target
that balances the quality-of-life benefit1,28,29 and the poorer
outcomes associated with targeting a higher hemoglobin
goal in CKD and ESRD populations.5,7 These data suggest
that the dose of epoetin-a should play an increasing role
in discussions to determine best policy-maximizing safety.
Although future investigations on the impact of dose on
outcomes may suggest a maximum dose for all patients
or separate maximum doses for specific subgroups, these
data suggest that among patients who do not achieve their
targeted goal for hemoglobin, consideration should be given
toward limiting dose escalation. For patients who do not
respond to lower doses of epoetin-a, the final hemoglobin
achieved may not be as important as the maximum doses
required.
MATERIALS AND METHODS
Study subjects
The Correction of Hemoglobin and Outcomes in Renal Insuffi-
ciency was a randomized trial comparing the effect of treatment
with epoetin-a to one of two hemoglobin targets on the composite
end point of death, congestive heart failure, stroke, and myocardial
infarction in CKD patients. Methods, baseline characteristics,
and results of CHOIR have been reported.5 Inclusion criteria
were hemoglobin o11.0 g/100 ml and modification of diet in
renal disease glomerular filtration rate of 15–50 ml/min/1.73 m2
(refs. 30,31)
Two landmark analyses were performed. To be included in either
analysis, subjects needed to be free of the composite event at the
796 Kidney International (2008) 74, 791–798
o r i g i n a l a r t i c l e LA Szczech et al.: Epoetin-a dose, achieved hemoglobin, and outcomes
landmark, receive epoetin-a, and have X1 post-baseline hemo-
globin measurement. Of the 1432 subjects randomized, 25 were
excluded because they had not received epoetin-a or obtained post-
baseline hemoglobin measurement. In the 4- and 9-month land-
mark analyses, 147 and 350 subjects were excluded, respectively,
because they had events or terminated the study before this
landmark. The populations for these analyses were 1260 and 1057
subjects.
Measurements
Subjects in CHOIR were randomized to hemoglobin targets
of 11.3 or 13.5 g/100 ml utilizing different dosing algorithms
and were administered weekly or biweekly epoetin-a
subcutaneously. Information on ESA dose and hemoglobin
were collected at least biweekly.
Definitions
Three categories of achieved hemoglobin (gm/100 ml) were
considered: o11.1, X11.1 and o13.1, and X13.1. These
categories were chosen on the basis of CHOIR’s dosing
algorithm dictating no change or decrease in dose if
hemoglobin exceeded 11.1 in the low-hemoglobin or
13.1 gm/100 ml in the high-hemoglobin group. Therefore,
these values defined a range in which subjects functionally
met target. Subjects achieved their respective targets if their
maximum hemoglobin (within the first 4 or 9 months for
each analysis) was X13.1 gm/100 ml in high-hemoglobin or
X11.1 gm/100 ml in low-hemoglobin group.
Erythropoietin-stimulating agent use was categorized as
high- or low-dose if the maximum dose (within the first 4 or
9 months of the study for each landmark analysis) was
X20,000 or o20,000 U (high vs low dose). This threshold
was chosen because CHOIR limited the dose of epoetin-a to
20,000 U/week.
Statistical analysis
Landmark analyses32,33 were performed to examine associa-
tions between achieved hemoglobin, epoetin-a dose, and
outcomes. Analyses were performed using both the compo-
site end point and death alone. As conclusions were similar,
only analyses using the composite end point are presented.
Landmark analyses are used to test for effects of a direct
treatment arm and associations between post-baseline vari-
ables and outcomes. In landmark analyses, subjects surviving
to the ‘landmark’ time are included. Post randomization but
‘pre-landmark’ values of potential predictors are summarized
and tested for association with outcomes.
The association between independent variables (that is,
data obtained post-baseline but prelandmark) and survival
are estimated from the landmark time point through the end
of follow-up using time-to-event analyses. This approach
eliminates biases introduced by defining early event as no-
response (hyporesponsiveness) and by including the time
before response as part of the survival time for responders
(lead-time bias). The interpretation of results is conditional
on a subject being free from the composite event before the
landmark. No hemoglobin or dose values after the landmark
time are utilized.
The landmarks of 4 and 9 months were chosen on
the basis of the qualitative observations that epoetin-a dose
and hemoglobin measurements stabilized at 4 months
and outcomes curves comparing treatment arms began to
separate at 9 months.5 The P-values of comparing the
treatment groups for time to composite event in the first 4 or
9 months are 0.59 and 0.44, respectively. Data before each
landmark were summarized to categorize subjects on the
basis of their ability to achieve hemoglobin target and use of
high-dose ESA using the above definitions.
Multivariable Cox hazards regression analyses were
performed. Initial models tested the additive association of
achieved hemoglobin, high-dose ESA, or both to the effect of
treatment arm. Subsequently, an adjusted model including
variables that significantly different between groups was
developed. Interactions between achieved hemoglobin, high-
dose ESA, and treatment arm were tested.
A proportional hazards Cox model was also fit to
assess the descriptive effect of average dose on the out-
come. Restricted cubic splines for average dose were used
in the Cox regression model within each group without
adjusting other variables.34,35 Average epoetin-a dose for each
patient for both the 4- and 9-month landmark analyses were
calculated using all values preceding each landmark time
point. The log-hazard ratios with their confidence intervals
for increasing average epoetin-a dose were plotted against
average dose for each target group and landmark analysis
separately. As a complement to the confidence intervals (also
plotted on a log scale), frequency distributions of patients
with average dose requirements within each treatment group
were overlaid on the curves to assist in the interpretation of
the curves.
All statistical analyses were performed using SAS (version
8.2, SAS Institute, Cary, NC, USA).
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